Traumatic Brain Injury (TBI) remains a leading cause of mortality and long-term disability worldwide, presenting a silent epidemic that incurs massive economic and social costs. For decades, the clinical categorization of TBI has relied heavily on the Glasgow Coma Scale (GCS), a tool developed in 1974 to assess consciousness levels. While the GCS remains effective for acute triage and determining the immediate need for airway protection, it is increasingly recognized as an insufficient metric for characterizing the heterogeneous pathophysiology of brain trauma. This is particularly evident in the stratification of patients into mild, moderate, or severe categories, a system that frequently fails to capture the complexity of mild cases (mTBI), where patients may experience debilitating, persistent cognitive and emotional deficits despite having negative non-contrast computed tomography (CT) and standard magnetic resonance imaging (MRI) scans.

This diagnostic gap—often termed the invisible injury—hinders the development of targeted therapies and accurate prognostication. The failure of conventional imaging lies in its inherent resolution limits; it is designed to detect macroscopic structural failures such as skull fractures, large hematomas, or midline shifts. It is largely blind to the microscopic axonal shearing and cellular distress that may underpin TBI sequelae.

Recent histopathological and advanced imaging studies have clarified that these invisible injuries are often driven by specific cellular and physiological mechanisms: astrogliosis (the reactive scarring of support cells), myelin degradation, and neurovascular dysfunction. For instance, a landmark study by Benjamini et al.2 demonstrated that multidimensional MRI sequences can now map astrogliosis in the living human brain, revealing distinct patterns of microscopic scarring that were previously visible only at autopsy. This allows for the visualization of the brain's wound healing response, which, when dysregulated, prevents neural recovery. Similarly, Russell-Schulz et al.12 identified that individuals with chronic mTBI and persistent symptoms exhibit a quantifiable decrease in myelin water fraction (MWF). This metric indicates a subtle but significant loss of the myelin sheath integrity, akin to the fraying of insulation on a wire, which standard scans miss entirely. Furthermore, injury frequently disrupts neurovascular coupling—the precise coordination between neuronal activity and blood flow—leading to perfusion deficits that persist even when structural integrity appears intact. These specific pathological substrates—scarring, demyelination, and hypoperfusion—are the true targets that newer modalities must detect to move the field forward.

Recent years have marked a critical inflection point in addressing these limitations. The field is transitioning from a reliance on static, macro-structural imaging to advanced modalities capable of interrogating specific microstructure, metabolic states, and functional network integrity. This shift is formalized by the 2024 National Institute of Neurological Disorders and Stroke (NINDS) Traumatic Brain Injury Classification and Nomenclature Initiative. The initiative’s Imaging Working Group has proposed a new framework that integrates clinical signs, blood-based biomarkers, and advanced neuroimaging into a cohesive diagnostic model.10 This review focuses on the specific neuroimaging advances that underpin this new framework and could facilitate the move toward precision medicine.